Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) has been given an average recommendation of "Buy" by the eleven analysts that are covering the company, MarketBeat Ratings reports. Eleven research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $28.10.
Several analysts have recently issued reports on the stock. Needham & Company LLC began coverage on shares of Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They set a "buy" rating and a $35.00 target price on the stock. Truist Financial began coverage on shares of Centessa Pharmaceuticals in a research report on Monday, July 21st. They set a "buy" rating and a $30.00 target price on the stock. Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Chardan Capital restated a "buy" rating and set a $30.00 target price on shares of Centessa Pharmaceuticals in a research report on Tuesday. Finally, Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, May 8th. They set an "outperform" rating and a $6.00 target price on the stock.
Check Out Our Latest Stock Report on Centessa Pharmaceuticals
Centessa Pharmaceuticals Stock Performance
Shares of CNTA stock traded up $0.09 during mid-day trading on Friday, reaching $17.23. 291,839 shares of the company's stock traded hands, compared to its average volume of 958,719. Centessa Pharmaceuticals has a 12 month low of $9.60 and a 12 month high of $19.09. The firm has a 50 day moving average price of $14.53 and a two-hundred day moving average price of $14.49. The company has a debt-to-equity ratio of 0.28, a quick ratio of 14.37 and a current ratio of 14.37. The firm has a market capitalization of $2.30 billion, a PE ratio of -9.63 and a beta of 1.48.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.03). On average, research analysts forecast that Centessa Pharmaceuticals will post -1.6 EPS for the current year.
Insider Transactions at Centessa Pharmaceuticals
In related news, insider Mario Alberto Accardi sold 15,000 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $14.00, for a total transaction of $210,000.00. Following the sale, the insider directly owned 216,485 shares of the company's stock, valued at $3,030,790. This represents a 6.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $12.71, for a total transaction of $699,050.00. Following the transaction, the chief executive officer owned 221,017 shares of the company's stock, valued at $2,809,126.07. This trade represents a 19.93% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 230,322 shares of company stock worth $3,196,684. 7.09% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of CNTA. JPMorgan Chase & Co. boosted its holdings in shares of Centessa Pharmaceuticals by 40.1% in the 4th quarter. JPMorgan Chase & Co. now owns 190,385 shares of the company's stock valued at $3,189,000 after buying an additional 54,482 shares in the last quarter. Wellington Management Group LLP raised its position in Centessa Pharmaceuticals by 14.4% in the 4th quarter. Wellington Management Group LLP now owns 115,107 shares of the company's stock valued at $1,928,000 after purchasing an additional 14,494 shares during the last quarter. Geode Capital Management LLC raised its position in Centessa Pharmaceuticals by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 57,257 shares of the company's stock worth $959,000 after buying an additional 660 shares during the last quarter. Legal & General Group Plc purchased a new position in Centessa Pharmaceuticals during the 4th quarter worth $1,263,000. Finally, Barclays PLC raised its position in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after buying an additional 4,952 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company's stock.
Centessa Pharmaceuticals Company Profile
(
Get Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
Featured Articles
Before you consider Centessa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.
While Centessa Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access